trending Market Intelligence /marketintelligence/en/news-insights/trending/qP6ehNnZl_Gh8Gy-QvWHhQ2 content esgSubNav
In This List

US FDA accepts VBI Vaccines application for brain tumor drug

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


US FDA accepts VBI Vaccines application for brain tumor drug

The U.S. Food and Drug Administration accepted VBI Vaccines Inc.'s investigational new drug application for VBI-1901, an immunotherapy to treat glioblastoma multiforme.

Glioblastoma multiforme is the most common and aggressive malignant primary brain tumors in humans.

VBI Vaccines intends to evaluate the drug in the second half of 2017 in a phase 1/2a clinical trial in patients with recurrent glioblastoma multiforme.